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Abstract 
Background: Atrial fibrillation (AF) and chronic kidney disease (CKD) are associated with an 
increased risk of ischemic stroke. The aim of this study was to compare the clinical 
characteristics, the incidence of left atrial appendage (LAA) thrombus and its predictors, and 
spontaneous echo contrast (SEC) in a population of patients with AF depending on estimated 
glomerular filtration rate (eGFR) values. 
Methods: This study included 1962 patients who underwent transesophageal echocardiographic 
examination (TEE) prior to cardioversion or ablation in the years 2014–2018 in three cardiac 
centers. 
Results: More than a quarter of AF patients had decreased eGFR (< 60 mL/min/1.73 m2) and 
were characterized as a high-risk population, with more comorbidities, higher thromboembolic 
and bleeding risk compared to those with normal renal function. Oral anticoagulation (OAC) was 
prescribed in 97% and 93% of patients with decreased and normal eGFR, respectively, with a 
higher prevalence of prescribed non-vitamin K antagonist oral anticoagulants (NOACs). The 
incidence of LAA thrombus (24%, 9% and 4%) and SEC (25%, 25% and 19%) increases 
simultaneously with a decrease in eGFR (< 30, 30–59 and > 60 mL/min/1.73 m2, respectively). 
  
Among patients prescribed reduced doses of NOAC, those with decreased eGFR were more often 
observed with LAA thrombus (10% vs. 2.5%). Non-paroxysmal AF, heart failure and previous 
bleeding were predictors of LAA thrombus, irrespective of eGFR value. CKD was the predictor 
of LAA thrombus in all patients including those with non-paroxysmal AF, males, without 
diabetes, without hypertension and with CHA2DS2-VASc < 2. 
Conclusions: Despite OAC, patients with concomitant AF and CKD remain at high risk for LAA 
thrombus formation.  
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Introduction 
 Atrial fibrillation (AF) occurs in approximately 3% adults aged 20 years or older with a 
greater prevalence in the elderly and patients with greater comorbid burden [1, 2]. It is an 
important risk factor for ischemic stroke since it associates with a 5-fold higher risk of stroke 
compared with the general population [3]. Tromboembolic events were identified in about 12% 
of cases for AF patients [4]. Anticoagulation treatment with vitamin K antagonists (VKAs) or 
non-VKA oral anticoagulants (NOACs), reducing the incidence of stroke and mortality [5]. 
Chronic kidney disease (CKD) alone is associated with a higher incidence of both strokes and 
bleeding [6, 7]. Moreover, patients with advanced CKD were excluded in large clinical trials 
(trials with dabigatran, rivaroxaban, and edoxaban excluded patients with an estimated 
glomerular filtration rate (eGFR) < 30 mL/min/1.73 m2, with apixaban — those with eGFR were 
< 25 mL/min/1.73 m2 or creatinine > 2.5 mg/dL) [8–11]. Kidney function should be regularly 
monitored in AF patients on oral anticoagulants (OACs) to allow dose adaptation and to estimate 
risk of complications [12].   
 Previous studies suggest that the incidence of LAA thrombi or SEC is up to 29% [13].  
The aim of the present study was to compare the incidence of the left atrial appendage (LAA) 
thrombi and spontaneous echo contrast (SEC) in a population of patients with AF who underwent 
transesophageal echocardiographic (TEE) examination prior to cardioversion or ablation 
depending on eGFR, a comparison of clinical characteristic of patients according to eGFR and 
determination of risk factors of LAA thrombi. 
 
Methods 
Study population 
 The study included consecutive patients with AF undergoing TEE before cardioversion or 
ablation between 2014 and 2018 from three large cardiac centers in Poland (an academic, military 
  
and district hospitals). In the academic department, TEE was performed routinely in all patients 
regardless of the duration of AF and the anticoagulant therapy. In the military and district 
hospitals, TEE was performed in cases when there was doubt regarding the timing of 
anticoagulant treatment and patient compliance. All TEE studies were performed by certified 
echocardiographers (certified with accreditation of the Section of Echocardiography of the Polish 
Cardiac Society), using EPIQ 7 Ultrasound Machine® (Philips Medical Systems, Andover, 
Massachusetts, United States), iE33 Ultrasound Machine® (Philips Medical Systems), General 
Electric Vivid 7 (GE Healthcare, Milwaukee, Wisconsin, United States) or E95 Ultrasound 
Machine® (GE Healthcare). Written informed consent for TEE was obtained from all patients. 
 Data on the clinical characteristics of patients, echocardiographic findings, laboratory 
results were retrospectively retrieved from patients’ medical history. The study protocol was 
approved by the Bioethics Committee. In addition, due to the retrospective nature of the study 
and the lack of additional interventions, the Committee waived the requirement to obtain separate 
consent from each patient to participate in the study. 
 The current analysis included only patients with data on baseline eGFR. This was 
estimated based on creatinine measurement at hospital admission (i.e. before TEE), using the 
Modification of Diet in Renal Disease (MDRD) Study equation. Patients were divided into three 
groups according to eGFR (< 30 mL/min/1.73 m2, 30–59 mL/min/1.73 m2 and ≥ 60 mL/min/1.73 
m2 (1432 patients). However, due to the small number of patients in the group with eGFR < 30 
mL/min/1.73 m2, the multivariate logistic regression analysis of the two groups are included 
(eGFR ≥ 60 mL/min/1.73 m2 and < 60 mL/min/1.73 m2).  
 
Statistical analysis 
Data is presented as a median and interquartile range (IQR) or number of patients and 
percentages where appropriate. The statistical significance of differences in medians was analyzed 
using the Kruskal-Wallis test. Frequencies of parameters or events were compared using the chi-
squared test or the Fisher exact test, as appropriate. For all tests, a p value < 0.05 was considered to 
be statistically significant. To determine predictors of LAA thrombus formation, univariate and 
multivariate logistic regression analyses were performed. Only variables that were available for 
more than 88% of patients were included in the logistic regression analysis. Statistical analysis was 
performed with StatsModels: Statistic in Python — v0.10.1 documentation. 
 
 
 
 
  
Results 
 A total of 1962 patients are included in the study and were divided into three groups: 
eGFR: < 30 mL/min/1.73 m2 (21 patients), 30–59 mL/min/1.73 m2 (509 patients) and > 60 
mL/min/1.73 m2 (1432 patients).  
 
Basic characteristic 
 Compared to other groups, patients with eGFR < 60 mL/min/1.73 m2 were older, more 
often suffered from hypertension, diabetes, coronary artery disease, peripheral vascular disease, 
heart failure, cancer and were more often were female. Moreover, the incidence of previous 
thromboembolic complications definied as composite of stroke/transient ischemic attack (TIA) 
and/or peripheral embolism as well as hemorrhagic events were higher in patients with the lowest 
value of eGFR. Detailed clinical characteristics of the groups are presented in Table 1.  
 Non-vitamin K antagonist oral anticoagulants were least often prescribed in the group 
with eGFR < 30 mL/min/1.73 m2 with a higher prevalance of low-dose NOAC prescription. 
There were no significant differences in the frequency of antiplatelet therapy or bridging therapy 
with heparin among all eGFR groups.  
 
Comparison of LAA thrombi prevalence 
 The incidence of LAA thrombi was more than twice as high in patients with eGFR 30–60 
mL/min/1.73 m2 than in those with > 60 mL/min/1.73 m2 (9% vs. 4%, respectively). In a 
relatively small group of patients with eGFR < 30 mL/min/1.73 m2 thrombi were present in 
almost a quarter of patients (24%). In addition, the lowest LAA emptying velocity were observed 
in the group of patients with eGFR < 30 mL/min/1.73 m2 (31 vs. 42 vs. 50 cm/s, respectively). 
Detailed therapeutic characteristics and echocardiographic findings of the eGFR groups are 
presented in Table 2. 
 
Predictors of LAA thrombus 
 On multivariate logistic regression, for the whole study group, eGFR was one of the 
predictors of LAA thrombus (p = 0.04). The other predictors were age, non-paroxysmal AF, heart 
failure, previous bleeding (Table 3), similar to patients with eGFR > 60 mL/min/1.73 m2 (Table 
4A). In those with eGFR < 60 mL/min/1.73 m2, non-paroxysmal AF, hypertension, heart failure 
and previous bleeding were the predictors of LAA thrombus (Table 4B).  
 Chronic kidney disease was the predictor of LAA thrombus in all patients as well as in 
those with non-paroxysmal AF (but not with paroxysmal AF), in males (but not in females), 
without diabetes, without hypertension and with CHA2DS2-VASc < 2 i.e. groups not included in 
  
classic risk factors (Fig. 1). Among patients with LAA thrombus no differences retaled to OAC 
treatment were observed between patients with eGFR < 60 mL/min/1.73 m2 and eGFR > 60 
mL/min/1.73 m2 (Table 5). Among patients on reduced dose of NOAC, LAA thrombus occured 
more often in patients with eGFR < 60 mL/min/1.73 m2 than in those with eGFR > 60 
mL/min/1.73 m2 (Table 6).  
 
Comparison of patients without OAC 
 Analyzing patients who were not treated with OAC (neither VKA nor NOAC) (Table 7), 
the incidence of LAA thrombus was higher and LAA emptying velocity was lower in patients 
with eGFR < 60 mL/min/1.73 m2 than in those with eGFR < 60 mL/min/1.73 m2. Patients with 
eGFR < 60 mL/min/1.73 m2 more often had persistent AF and heart failure as compared to those 
with normal eGFR. Median CHA2DS2-VASc score was 2 in patients with eGFR < 60 
mL/min/1.73 m2 and 1 in patients with eGFR ≥ 60 mL/min/1.73 m2. More than 50% of patients 
in both groups were found to be at high thromboembolic risk (CHA2DS2-VASc score ≥ 2).  
 
Discussion  
 The major findings of the present study are as follows. First, more than a quarter of AF 
patients had decreased eGFR (< 60 mL/min/1.73 m2) and simultaneously were characterized as a 
high-risk population, with more comorbidities, higher thromboembolic and bleeding risk 
compared to those with normal renal function. Second, OAC was prescribed in approximately 
97% of patients with decreased eGFR (90.5% of patients with eGFR < 30 mL/min/1.73 m2). The 
higher prevalence of prescribed NOAC was observed among patients with eGFR 30–59 
mL/min/1.73 m2. Importantly, among patients prescribed with reduced doses of NOAC, those 
with eGFR < 60 mL/min/1.73 m2 were more often observed with LAA thrombus. Third, the most 
important finding was that CKD was the predictor of LAA thrombus in all patients as well as in 
the group that are not included in classic risk factors. 
 Numerous observational studies yielded conflicting results for OAC regarding which of 
the two types of anticoagulant drug, NOAC vs. VKA, is preferable for patients with decreased 
eGFR. In the present study, among patients with LAA thrombus, there was no difference 
reflected to OAC treatment between patients with eGFR < 60 and ≥ 60 mL/min/1.73 m2. It is in 
line with a previous study [14] which proved that none of the OAC regimens predicted LAA 
thrombus in patients with AF, as well as with other studies focused on thromboembolic risk 
among AF patients with CKD [15–17]. Pivotal randomized controlled trials have established that 
NOAC are superior, however without statistical significance, to VKA among patients with CKD 
in preventing thromboembolic events. The ROCKET AF study indicates that, when compared 
  
with warfarin, rivaroxaban was non-inferior in preventing stroke or systemic embolism. Among 
patients with CrCl 30–49 mL/min, the primary endpoint of stroke or systemic embolism occurred 
in 2.32 per 100 patient-years with rivaroxaban 15 mg/day vs. 2.77 per 100 patient-years with 
warfarin, whereas among those with CrCl ≥ 50 mL/min, the primary endpoint of stroke or 
systemic embolism occurred in 1.57 per 100 patient-years with rivaroxaban 20 mg/day vs. 2.00 
per 100 patient-years with warfarin [18]. The ARISTOTLE study shows that apixaban at doses of 
5 mg twice daily in eGFR categories > 80, > 50 to 80, ≤ 50 mL/min/1.73 m2 was generally 
superior in preventing thromboembolic events with no significant interaction between the 
treatment effect [19]. According to the RE-LY study, the annual rates of thromboembolic events 
among patient eGFR categories > 80, 50 to < 80, < 50 mL/min/1.73 m2 were lower with 
dabigatran 150 mg and similar with 110 mg twice daily compared with warfarin without 
significant heterogeneity in subgroups defined by renal function (interaction [20]. However, 
another sub-analysis of the RE-LY trial data showed a significantly faster rate of decline in renal 
function in patients on VKA compared with those on dabigatran [21]. Using data from the IMS 
Disease Analyzer Germany study, Posch et al. [22] proved that exposure to VKA is associated 
with accelerated eGFR decline. In 7409 patients with VKA exposure, real failure progression was 
significantly faster compared to patients without VKA exposure (5-year absolute eGFR loss from 
baseline: 6.0 vs 4.5 mL/min/1.73 m2) [22]. It has been suggested that VKA may lead to decreased 
renal function via repeated subclinical glomerular hemorrhages or through accelerated tissue or 
vascular calcification [23].  
 There is no conclusive research that has determined the superiority of one of the NOAC 
drugs. Noteworthy, all NOAC are at least partly eliminated by the kidneys. In contrast to 
dabigatran (80%) and rivaroxaban (35%), apixaban is less dependent on renal elimination (27%) 
and is labeled for use in end-stage kidney disease. It may explain results from a Falissard et al. 
[24] study, in which apixaban was more likely to be prescribed than other NOACs in patients 
with decreased renal function. Based on online an survey created to analyze the opinion of the 
role of OAC in various clinical settings, edoxaban and apixaban were the favorites for patients 
with AF and moderate CKD [25]. In the present study, apixaban was prescribed more often in 
patients with kidney failure than in patients with normal kidney function. However, the 
prevalence of apixaban therapy was the lowest among all NOACs.  
 Recent publications have demonstrated the limitation of the CHA2DS2-VASc score for 
predicting future strokes in patients with AF [26]. There are conflicting data as to whether the 
integration of renal function parameters into CHA2DS2-VASc score could improve its predictive 
value. Some of studies suggest that the predictive value of CHA2DS2-VASc score is not 
improved by the addition of renal status because the factors within CHA2DS2-VASc are 
  
themselves related to renal dysfunction [27]. On the other hand, previous results from Global 
Anticoagulant Registry in the FIELD-Atrial Fibrillation (GARFIELD-AF) registry shows that 
moderate/severe CKD is independently associated with a higher risk of stroke/systemic embolism 
[28]. These findings are consistent with a previous study evaluating new thromboembolic risk 
score i.e. CHA2DS2-VASc-RAF score included two additional parameters i.e. renal dysfunction 
and AF type. Both variables proved strong, independent predictors of LAA thrombus on TEE and 
improve thromboembolic risk stratification [29]. Moreover, an inverse correlation between eGFR 
values and LAA thrombus occurrence were observed among patients included in the current 
study (24%, 9% and 4% of patients with eGFR< 30, 30–59 and ≥ 60 mL/min/1.73 m2, 
respectively). This is in line with study by Kizawa et al. [30], that examined 581 AF patients with 
CKD stages 1–4. The prevalence of thrombogenic milieu (LA thrombus, dense spontaneous echo 
contrast, or LAA a velocity ≤ 25 cm/s) increased with decreasing eGFR (4%, 18%, 36%, and 
86% for each group, p < 0.001). Moreover, multivariate logistic regression analysis revealed that 
every 10 mL/min/1.73 m2 decrement in eGFR was a significant independent correlate of 
thrombogenic milieu (OR 0.80, p = 0.005) [30]. 
 It is unclear, whether patients with decreased renal function and AF benefit from OAC to 
the same extent as those with normal kidney function. Current evidence suggests that patients 
with AF who have CKD with eGFR > 15 mL/min/1.73 m2 should be treated with OAC if they 
have an at least an intermediate risk of embolization, as assessed with the CHA2DS2-VASc score 
[31]. In the present study, 98% of patients with decreased renal function treated with OAC were 
at moderate or high risk (CHA2DS2-VASc score ≥ 2). Among high risk patients in whom OAC 
are recommended, thrombus was more frequent in patients with lower eGFR. Moreover, among 
patients who were not treated with OAC LAA thrombus occurred more often in patients with 
eGFR < 60 mL/min/1.73 m2.  
 Independent predictors for LAA thrombus formation included the following clinical risk 
factors — non-paroxysmal AF, hypertension, heart failure, previous bleeding in patients with 
eGFR < 60 mL/min/1.73 m2, and age, non-paroxysmal AF, heart failure, previous bleeding in 
those with eGFR ≥ 60 mL/min/1.73 m2. This is consistent with the high risk associated with such 
comorbidities in AF patients [32–34].  
 Based on previous meta-analysis by Wang et al. [35], patients eligible for a reduced dose 
of NOAC are at elevated risk of thromboembolic complications when compared to those eligible 
for full dose of NOAC (2.70% vs. 4.35%, respectively). In the current study it was confirmed that 
patients with reduced NOAC a prevalence of LAA thrombus is higher in patients with lower 
eGFR. 
Therefore, there is a particular need to use adequate OAC treatment in patients with CKD.  
  
 
Conclusions 
 The incidence of LAA thrombi was higher in patients with lower eGFR. eGFR was one of 
the predictors of LAA thrombus. CKD was the predictor of LAA thrombus in all patients as well 
as in patients with non-paroxysmal AF, in males, without diabetes, without hypertension and with 
CHA2DS2-VASc < 2 that is in groups which are not included in classic risk factors.  
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Table 1. Clinical characteristics in all groups according to eGFR. 
Variable 
Patients with 
eGFR < 30 (n = 
21) 
Patients with 
eGFR 30–59 (n 
= 509) 
Patients with 
eGFR ≥ 60 (n = 
1432) 
P 
Age [years] 71 [60–82] 67 [62–72] 61 [54–67] < 0.0001 
Female  9 (43%) 281 (55%) 424 (30%) < 0.0001 
BMI [kg/m2] 
26 [24–30]; n = 
14 
29 [26–32]; n = 
347 
29 [26–32]; n = 
1158 
0.34 
Obesity 4 (22%); n = 17 
145 (39%); n = 
370 
483 (40%); n = 
1204 
0.49 
Type of AF 
Paroxysmal AF  6 (29%) 197 (39%) 740 (52%) < 0.0001 
Persistent AF  11 (52%) 279 (55%) 622 (43%) < 0.0001 
Permanent/long-standing 
persistent AF  
4 (19%) 33 (6.5%) 70 (4.9%) 0.02 
Concomitant diseases  
Hypertension 17 (81%) 395 (78%) 965 (67%) < 0.0001 
Dyslipidemia 5 (24%) 180 (35%) 532 (37%) 0.57 
Diabetes 6 (29%) 114 (22%) 243 (17%) 0.01 
CAD 6 (29%) 114 (22%) 240 (17%) 0.01 
Previous MI 5 (24%) 53 (10%) 88 (6.1%) < 0.0001 
Previous PCI/CABG 5 (24%) 55 (11%) 104 (7.3%) 0.002 
PAD 2 (11%); n = 18 
14 (3.4%); n = 
407 
29 (2.8%); n = 
1031 
0.11 
Vascular disease (CAD 
and/or PAD) 
7 (33%) 126 (25%) 263 (18%) 0.004 
  
Heart failure 9 (43%) 147 (29%) 250 (18%) < 0.0001 
Previous 
stroke/TIA/peripheral 
embolism  
3 (14%) 49 (9.6%) 85 (5.9%) 0.02 
Chronic respiratory disease 1 (5.6%); n = 18 
32 (7.9%); n = 
406 
54 (5.2%); n = 
1031 
0.15 
Liver disease  1 (5.6%); n = 18 
2 (0.5%); n = 
407 
19 (1.8%); n = 
1031 
0.06 
Malignancy 1 (6.7%); n = 15 
27 (8.7%); n = 
309 
39 (4.5%); n = 
869 
0.018 
Previous bleeding 4 (19%) 41 (8.1%) 56 (3.9%) < 0.0001 
Labile INR 0 (0%); n = 18 
9 (2.2%); n = 
407 
9 (0.9%); n = 
1031 
0.10 
Smoking 2 (13%); n = 15 
95 (31%); n = 
309 
282 (33%); n = 
869 
0.30 
Thromboembolic risk 
CHADS2 score 
2.2 ± 1.3 
2 [1–3] 
1.6 ± 1.2 
1 [1–2] 
1.2 ± 1.0 
1 [0–2] 
< 0.0001 
CHA2DS2-VASc score 
3.7 ±  2.0 
3 [3–5] 
3.1 ± 1.7 
3 [2–4] 
2.0 ± 1.5 
2 [1–3] 
< 0.0001 
CHA2DS2-VASc score 
= 0 
= 1 
= 2 
≥ 3 
 
0 (0%) 
3 (14.3%) 
2 (9.5%) 
16 (76%) 
 
15 (2.9%) 
77 (15%) 
115 (23%) 
302 (59%) 
 
231(16%) 
384 (27%) 
344 (24%) 
473 (33%) 
 
< 0.0001 
< 0.0001 
0.28 
< 0.0001 
HAS-BLED score 
2.8 ± 1.0 
3 [2–3]; n = 18 
1.8 ± 1.0 
2 [1–2]; n = 407 
1.1 ± 0.9 
1 [0–2]; n = 
1038 
< 0.0001 
  
HAS-BLED score 
= 0 
= 1 
= 2 
≥ 3 
 
0 (0%) 
1 (5.6%) 
7 (39%) 
10 (56%) 
 
34 (8.4%) 
150 (30%) 
175 (34%) 
146 (29%) 
 
336 (26%) 
623 (44%) 
404 (28%) 
69 (4.8%) 
 
< 0.0001 
< 0.0001 
< 0.0001 
< 0.0001 
Laboratory parameters 
Hemoglobin [g/dL] 
13 [12–14]; n = 
21 
14 [13–15]; n = 
490 
15 [14–15]; n = 
1418 
< 0.0001 
Hematocrit [%] 
39 [35–42]; n = 
18 
42 [39–45]; n = 
391 
43 [40–46]; n = 
1233 
< 0.0001 
Platelet count [K/μL] 
175 [156–199]; n 
= 21 
217 [179–253]; 
n = 488 
216 [182–252]; 
n = 1414 
0.01 
Creatinine [mg] 2.4 [2.0–5.4] 1.3 [1.1–1.4] 1.0 [0.9–1.1] < 0.0001 
GFR [mL/min/1.73 m2] 23 [11–28] 53 [46–57] 84 [71–90] < 0.0001 
INR (for patients on VKA) 
2.1 [2.0–2.4]; n = 
9 
2.3 [1.8–2.9]; n 
= 147 
2.3 [1.8–2.9]; n 
= 461 
0.63 
INR (for patients on VKA) 
- < 2.0 
- 2.0–3.0 
- > 3.0 
 
4 (44%) 
4 (44%) 
1 (11%) 
 
54 (37%) 
61 (41%) 
32 (22%) 
 
139 (30%) 
225 (49%) 
97 (21%) 
 
0.37 
0.35 
0.82 
APTT [s] 
34 [32–48]; n = 
17 
37 [32–45]; n = 
371 
35 [30–42]; n = 
1171 
< 0.0001 
AF — atrial fibrillation; APTT — activated partial thromboplastin time; BMI — body mass index; CABG — coronary 
artery bypass graft; CAD — coronary artery disease; MI — myocardial infarction; eGFR — estimated glomerular 
filtration rate; INR — international normalized ratio; PAD — peripheral artery disease; PCI — percutaneous coronary 
intervention; TIA — transient ischemic attack; VKA — vitamin K antagonists 
 
 
 
Table 2. Therapeutic characteristics and echocardiography findings in all groups according to 
eGFR.  
Variable 
Patients with 
eGFR < 30 (n = 
21) 
Patients with 
eGFR 30–59 (n = 
509) 
Patients with 
eGFR ≥ 60 (n = 
1432) 
P 
  
Type of procedure planned 
Cardioversion 9 (43%) 246 (48%) 479 (33%) <0.0001 
Ablation 12 (57%) 263 (52%) 953 (67%) <0.0001 
Antithrombotic treatment  
No OAC 2 (9.5%) 13 (2.6%) 102 (7.1%) 0.001 
VKA  9 (43%) 168 (33%) 503 (35%) 0.44 
NOAC  10 (48%) 328 (64%) 827 (58%) 0.01 
dabigatran 
rivaroxaban 
apixaban 
5 (24%) 
3 (14%) 
2 (9.5%) 
157 (31%) 
160 (32%) 
11 (2.2%) 
387 (27%) 
431 (30%) 
9 (0.6%) 
0.29 
0.18 
< 0.0001 
Reduced dose of NOAC 5 (24%) 53 (10%) 40 (2.8%) < 0.0001 
Bridging therapy with 
heparin 
1 (5.6%); n = 18 14 (3.4%); n = 407 70 (6.7%); n = 1031 0.05 
Antiplatelets  1 (5.6%); n = 18 19 (4.7%); n = 407 62 (6.0%); n = 1031 0.63 
Transthoracic echocardiography* 
Ejection fraction [%] 50 [25–55]; n = 5 
55 [50–60]; n = 
211 
58 [50–60]; n = 607 0.04 
Left atrial diameter [cm] 49 [48–52]; n = 6 
45 [42–48]; n = 
216 
45 [41–48]; n = 664 0.26 
Transesophageal echocardiography* 
Thrombus 5 (24%) 46 (9.0%) 57 (4.0%) < 0.0001 
LAA emptying velocity 
[cm/s] 
31 [25–55]; n = 7 
42 [29–64]; n = 
332 
50 [32–74]; n = 
1130 
< 0.0001 
SEC 5 (25%); n = 18 97 (25%); n = 392 
237 (19%); n = 
1233 
0.08 
  
eGFR — estimated glomerular filtration rate; LAA — left atrial appendage; OAC — oral 
anticoagulants; NOAC — non-vitamin K antagonist oral anticoagulants; SEC — spontaneous echo 
contrast; VKA — vitamin K antagonists 
 
 
 
Table 3. Logistic regression analyses of predictors of left atrial thrombus in the whole group of 
patients. 
Variable 
Univariate 
analysis 
Multivariate analysis 
OR 95% CI P 
Age < 0.0001 1.02 1.00–1.05 0.03 
Non-paroxysmal AF (vs. 
paroxysmal AF) 
< 0.0001 5.62 3.10–10.17 < 0.0001 
Dyslipidemia 0.02 0.72 0.45–1.15 0.16 
Diabetes 0.001 1.40 0.87–2.25 0.16 
Coronary artery disease 0.02 5.47 0.40–75.39 0.20 
Vascular disease 0.045 0.14 0.01–1.93 0.14 
Myocardial infraction 0.03 1.09 0.48–2.50 0.83 
Heart failure < 0.0001 2.22 1.42–3.47 < 0.0001 
Previous bleeding < 0.0001 2.97 1.56–5.65 0.001 
eGFR 0.001 0.9888 0.9782–0.9996 0.04 
AF — atrial fibrillation; CABG — coronary artery bypass graft; CI — confidence intervals; eGFR — estimated 
glomerular filtration rate; PCI — percutaneous coronary intervention; OR — odd ratio; TIA — transient ischemic 
attack; VKA — vitamin K antagonist 
 
 
 
Table 4. Logistic regression analyses of predictors of left atrial thrombus. 
A. Predictors of left atrial thrombus in the group of patients with eGFR 60 mL/min/1.73 m2 or 
more 
Variable 
Univaria
te 
analysis 
Multivariate analysis 
OR 95% CI P 
Age 0.001 1.03 1.00–1.06 0.047 
  
Non-paroxysmal AF (vs paroxysmal AF) < 0.0001 4.49 2.12–9.48 < 0.0001 
Diabetes < 0.0001 1.66 0.90–3.04 0.10 
Heart failure < 0.0001 2.35 1.31–4.23 0.004 
Previous bleeding 0.002 3.64 1.49–8.92 0.005 
B. Predictors of left atrial thrombus in the group of patients with eGFR of less than 60 
mL/min/1.73 m2  
Non-paroxysmal AF (vs. paroxysmal AF) < 0.0001 6.72 2.49–18.17 < 0.0001 
Hypertension 0.048 0.46 0.23–0.91 0.03 
Dyslipidemia 0.04 0.65 0.31–1.36 0.25 
Heart failure 0.002 2.25 1.18–4.27 0.01 
Previous bleeding 0.02 2.84 1.16–6.99 0.02 
AF — atrial fibrillation; CI — confidence intervals; OR — odds ratio; eGFR — estimated glomerular filtration rate 
 
 
Table 5. The distribution of anticoagulation treatment in patients with left atrial appendage (LAA) 
thrombus glomerular filtration rate less than 60 mL/min/1.73 m2 and 60 mL/min/1.73 m2 and more. 
Variable 
Patients with LAA thrombus 
GFR < 60 (n = 51) GFR ≥ 60 (n = 57) P 
No OAC 3 (5.9%) 3 (5.3%) 1.00 
VKA 23 (45%) 28 (49%) 0.85 
NOAC 25 (49%) 26 (46%) 0.85 
dabigatran 14 (46%) 14 (25%) 0.52 
rivaroxaban 12 (21%) 12 (21%) 0.64 
apixaban 0 (0%) 0 (0%) 1.00 
GFR — glomerular filtration rate; NOAC — non-vitamin K antagonist oral anticoagulants; OAC — oral 
anticoagulants; VKA — vitamin K antagonists 
 
  
Table 6. The distribution of left atrial appendage (LAA) thrombus in patients with reduced non-
vitamin K antagonist oral anticoagulants according to glomerular filtration rate. 
Variable 
Patients with reduced NOAC 
GFR < 30 (n = 5) GFR 30–59 (n = 53) GFR ≥ 60 (n = 40) P 
LAA thrombus 1 (20%) 5 (9.4%) 1 (2.5%) 0.001 
GFR — glomerular filtration rate; NOAC — non-vitamin K antagonist oral anticoagulants 
 
Table 7. Comparison of patients without oral anticoagulation according to glomerular filtration 
rate. 
Variable 
No OAC 
GFR < 60 (n = 15) GFR ≥ 60 (n = 102) P 
Age [years] 63 [58–71] 53 [38–60] 0.007 
Female 7 (47%) 28 (28%) 0.14 
BMI [kg/m2] 29 [27–31]; n = 12 27 [25–31]; n = 97 0.39 
Obesity 4 (27%) 31 (30%) 1.00 
Type of AF  
Paroxysmal AF  8 (53%) 89 (87%) 0.004 
Persistent AF  5 (33%) 11 (11%) 0.03 
Permanent/long-standing persistent AF  2 (13%) 2 (2.0%) 0.08 
Type of procedure planned 
Cardioversion 6 (40%) 17 (17%) 0.07 
Ablation 9 (60%) 85 (83%) 0.07 
Concomitant diseases  
Hypertension 8 (53%) 40 (39%) 0.40 
Dyslipidemia 1 (6.7%) 31 (30%) 0.07 
Diabetes 2 (13%) 3 (2.9%) 0.12 
CAD 3 (20%) 8 (7.8%) 0.15 
  
Previous myocardial infarction 2 (13%) 6 (5.9%) 0.27 
Previous CABG/PCI 2 (13%) 5 (4.9%) 0.22 
PAD 2 (13%) 1 (1.0%) 0.04 
Vascular disease (CAD and/or PAD) 3 (20%) 9 (8.8%) 0.18 
Heart failure 5 (33%) 10 (9.8%) 0.02 
Previous ischemic stroke/TIA 2 (13%) 2 (2.0%) 0.08 
Previous ischemic stroke/TIA/peripheral 
embolism  
2 (13%) 2 (2.0%) 0.08 
Chronic respiratory disease 1 (6.7%) 2 (2.0%) 0.34 
Liver disease  0 (0%) 0 (0%) 1.00 
Hyperthyroidism   1 (6.7%) 3 (2.9%) 0.43 
Hypothyroidism 3 (20%) 8 (7.8%) 0.15 
Malignancy 0 (0%) 1 (1.0%) 1.00 
Previous bleeding 4 (27%) 4 (3.9%) 0.009 
Smoking 5 (33%) 34 (33%) 1.00 
Thromboembolic risk 
CHADS2 score 1 [0.5–2] 0 [0–1] 0.007 
CHA2DS2-VASc score 2 [1–3] 1 [0–2] 0.01 
CHA2DS2-VASc score: 
= 0 
= 1 
= 2 
> 3 
 
0 (0%) 
6 (40%) 
4 (27%) 
5 (33%) 
 
24 (24%) 
23 (23%) 
25 (25%) 
30 (29%) 
 
0.04 
0.20 
1.00 
0.77 
  
HAS-BLED score 1 [1–3] 1 [0–1.8] 0.02 
HAS-BLED score: 
= 0 
= 1 
= 2 
> 3 
 
2 (13%) 
3 (20%) 
7 (47%) 
3 (20%) 
 
27 (27%) 
36 (35%) 
24 (24%) 
15 (15%) 
 
0.35 
0.38 
0.07 
0.70 
Laboratory parameters 
Hemoglobin [g/dL] 13 [12–15] 15 [14–15] 0.005 
Hematocrit [%] 41 [38–43] 44 [42–46] 0.003 
WBC [K/μL] 7.4 [6.6–8.6] 7.1 [6.1–8.8] 0.73 
Platelet count [K/μL] 254 [196–284] 228 [199–256] 0.41 
AST 25 [20–39]; n = 14 22 [19–27]; n = 93 0.27 
ALT 31 [21–46]; n = 14 32 [23–38]; n = 94 0.88 
Transthoracic echocardiography*  
Ejection fraction [%] 50 ± 0; n = 1 60 [55–62]; n = 17 0.29 
Left atrial diameter [cm] 44 [43–47]; n = 4 43 [40–45]; n = 44 0.71 
Transesophageal echocardiography* 
Thrombus 3 (20%) 3 (2.9%) 0.03 
LAA emptying velocity [cm/s] 56 [42–68]; n = 15 70 [49–87]; n = 99 0.04 
SEC 2 (13%) 7 (6.9%) 0.32 
*Performed during index hospitalization. AST — aspartate transaminase; AF – atrial fibrillation; ALT — alanine 
transaminase; BMI — body mass index; CABG — coronary artery bypass grafting; CAD — coronary artery disease; 
GFR — glomerular filtration rate; LAA — left atrial appendage; OAC — oral anticoagulants;  PAD — peripheral 
artery disease; PCI — percutaneous coronary intervention; SEC — spontaneous echo contrast; TIA — transient 
ischemic attack; WBC — white blood cells 
  
  
Figure 1. Forest plot of chronic kidney disease as predictor of left atrial appendage thrombus in 
atrial fibrillation patients depending on additional risk factors. 
 

